US Editionāshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
Summary by The Huntsville Item
2 Articles
2 Articles
All
Left
1
Center
Right
āshibio begins dosing in trial of andecaliximab for spinal cord injury
āshibio has commenced subject dosing in the Phase Ib trial, ANDECA-HO, assessing andecaliximab in spinal cord injury (SCI) patients.The post āshibio begins dosing in trial of andecaliximab for spinal cord injury appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
